MedTrace Logo

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

NCT06054217 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-04-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

Conditions

  • Meibomian Gland Dysfunction
  • Demodex Infestation of Eyelid
  • Blepharitis
  • Demodectic Blepharitis

Interventions

DRUG

Vehicle of TP-03

The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)

Sponsors & Collaborators

  • Tarsus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Mitchell C Shultz, MD · Shultz Chang Vision

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-06-15
Completion
2024-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054217 on ClinicalTrials.gov